Masticatory Myofascial Pain SyndromeNCT07774884
Does Addition of Medial Pterygoid Muscle Injection Improve the Outcome of Botulinum Toxin Therapy for Masticatory Myofascial Pain Syndrome?
A study testing conventional BoNT-A treatment and conventional treatment plus medial pterygoid injection in people with Masticatory Myofascial Pain Syndrome, run by Fayoum University at 1 site in Egypt.
Trial summary
Masticatory myofascial pain syndrome (MMPS) is a common and debilitating orofacial pain condition characterized by localized or referred pain originating from trigger points in the masticatory muscles. The condition significantly impairs quality of life, affecting mastication, speech, and psychosocial well-being. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Masticatory Myofascial Pain Syndrome
- What is being tested?
- conventional BoNT-A treatment and conventional treatment plus medial pterygoid injection
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 111 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2026to 1 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of myogenous TMD/myalgia according to DC/TMD.
- Pain modified by jaw movement, function, or parafunction.
- Familiar pain reproduced during standardized masseter/temporalis examination.
- Clinical evidence of medial pterygoid involvement.
- Medial pterygoid provocation reproduces the patient's familiar pain.
- Symptoms present for at least 3 months.
- No major competing odontogenic cause for the patient's pain.
Who cannot join
- Predominantly arthrogenous TMD.
- Trigeminal neuralgia or other neuropathic facial pain.
- Active systemic inflammatory or infectious disease affecting the masticatory muscles.
- Significant neuromuscular disease.
- Pregnancy or breastfeeding.
- Previous BoNT-A injection into the relevant masticatory muscles during the predefined washout period.
Show all 11Show fewer
- Known hypersensitivity to the study medication or formulation components.
- Local infection at the injection site.
- Significant bleeding disorder.
- Clinically significant uncontrolled anticoagulation.
- Previous major surgery involving the medial pterygoid region that could alter anatomy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Islam Kassem, PhD contact
Egypt1 site
MUST University
Cairo, Cairo Governorate, 21523
Alshaimaa shabaan, 01006047940, aas16@fayoum.edu.eg
About this study
Official title: Does Addition of Medial Pterygoid Muscle Injection Improve the Outcome of Botulinum Toxin Therapy for Masticatory Myofascial Pain Syndrome? A Randomized Controlled Clinical Trial
Masticatory myofascial pain syndrome (MMPS) is a common and debilitating orofacial pain condition characterized by localized or referred pain originating from trigger points in the masticatory muscles. The condition significantly impairs quality of life, affecting mastication, speech, and psychosocial well-being. The masseter and temporalis muscles are the most frequently targeted muscles in conventional botulinum toxin type A (BoNT-A) therapy for MMPS; however, the medial pterygoid muscle, a primary jaw-closing muscle, is often overlooked due to its deep anatomical location and the technical challenges associated with its injection.
Read the detailed description
Current evidence supports the efficacy of BoNT-A in reducing pain and improving mandibular function in patients with localized MMPS. However, the specific contribution of targeted medial pterygoid injection to overall treatment outcomes remains unclear. This study aims to address this gap by evaluating whether the addition of targeted medial pterygoid injection enhances the clinical efficacy of conventional masseter and temporalis BoNT-A therapy.
- Conditions
- Masticatory Myofascial Pain Syndrome
- Being tested
- conventional BoNT-A treatment, Placebo, conventional treatment plus medial pterygoid injection
- Keywords
- Masticatory myofascial pain syndrome, masseter muscle, Temporalis muscle, medial pterygoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
conventional BoNT-A treatmentProcedure or surgery
botulinum toxin type A injection into the bilateral masseter and temporalis muscles
PlaceboProcedure or surgery
placebo/sham injection protocol
conventional treatment plus medial pterygoid injectionProcedure or surgery
masseter and temporalis injections as Group A, in addition to targeted injection of the clinically involved medial pterygoid muscle
| Study group | Role | What they receive |
|---|---|---|
| Group A | Active comparator | botulinum toxin type A injection into the bilateral masseter and temporalis muscles Receives: Procedure: conventional BoNT-A treatment |
| Group B | Experimental | masseter and temporalis injections , in addition to targeted injection of the clinically involved medial pterygoid muscle Receives: Procedure: conventional treatment plus medial pterygoid injection |
| Group C | Placebo comparator | predefined placebo/sham injection protocol Receives: Procedure: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
pain intensity
a 10-point visual analogue scale (VAS), where 0 revealed no pain and 10 represented the worst imaginable pain
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Mar 2027 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Masticatory Myofascial Pain SyndromeStudies of the same condition, open and under way.
- More trials run by Fayoum UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 111 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fayoum University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Alshaimaa Ahmed shabaan, Fayoum University
- Investigators
- Alshaimaa Mohamed, Principal investigator, Fayoum University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07774884
- Sponsor's protocol ID
- MP injection Botox
- Status last verified
- Aug 2026
- First submitted
- 16 Aug 2026
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Li K, Tan K, Yacovelli A, Bi WG. Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta-analysis of randomized controlled trials. J Oral Rehabil. 2024 May;51(5):886-897. doi: 10.1111/joor.13648. Epub 2023 Dec 27.
PubMed 38151884Yoshida K. Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System. Toxins (Basel). 2022 Apr 14;14(4):282. doi: 10.3390/toxins14040282.
PubMed 35448891
Study at a glance
From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does Addition of Medial Pterygoid Muscle Injection Improve the Outcome of Botulinum Toxin Therapy for Masticatory Myofascial Pain Syndrome? A Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07774884
- Acronym / sponsor ID
- MP injection Botox
- Conditions
- Masticatory Myofascial Pain Syndrome
- Keywords
- Masticatory myofascial pain syndrome, masseter muscle, Temporalis muscle, medial pterygoid
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 111 participants (estimated)
- Lead sponsor
- Fayoum UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 Mar 2027 (estimated)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 19 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Masticatory myofascial pain syndrome (MMPS) is a common and debilitating orofacial pain condition characterized by localized or referred pain originating from trigger points in the masticatory muscles. The condition significantly impairs quality of life, affecting mastication, speech, and psychosocial well-being. The masseter and temporalis muscles are the most frequently targeted muscles in conventional botulinum toxin type A (BoNT-A) therapy for MMPS; however, the medial pterygoid muscle, a primary jaw-closing muscle, is often overlooked due to its deep anatomical location and the technical challenges associated with its injection.
Detailed description
Current evidence supports the efficacy of BoNT-A in reducing pain and improving mandibular function in patients with localized MMPS. However, the specific contribution of targeted medial pterygoid injection to overall treatment outcomes remains unclear. This study aims to address this gap by evaluating whether the addition of targeted medial pterygoid injection enhances the clinical efficacy of conventional masseter and temporalis BoNT-A therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group A | Active comparator | Procedure: conventional BoNT-A treatmentbotulinum toxin type A injection into the bilateral masseter and temporalis muscles |
| Group B | Experimental | Procedure: conventional treatment plus medial pterygoid injectionmasseter and temporalis injections , in addition to targeted injection of the clinically involved medial pterygoid muscle |
| Group C | Placebo comparator | Procedure: Placebopredefined placebo/sham injection protocol |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Diagnosis of myogenous TMD/myalgia according to DC/TMD.
- Pain modified by jaw movement, function, or parafunction.
- Familiar pain reproduced during standardized masseter/temporalis examination.
- Clinical evidence of medial pterygoid involvement.
- Medial pterygoid provocation reproduces the patient's familiar pain.
Key exclusion criteria (11 listed)
- Predominantly arthrogenous TMD.
- Trigeminal neuralgia or other neuropathic facial pain.
- Active systemic inflammatory or infectious disease affecting the masticatory muscles.
- Significant neuromuscular disease.
- Pregnancy or breastfeeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| conventional BoNT-A treatmentbotulinum toxin type A injection into the bilateral masseter and temporalis muscles | Procedure or surgery | Group A |
| Placeboplacebo/sham injection protocol | Procedure or surgery | Group C |
| conventional treatment plus medial pterygoid injectionmasseter and temporalis injections as Group A, in addition to targeted injection of the clinically involved medial pterygoid muscle | Procedure or surgery | Group B |
Primary outcome
pain intensity
Time frame: 6 months
a 10-point visual analogue scale (VAS), where 0 revealed no pain and 10 represented the worst imaginable pain
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
- Results publication: PubMed 38151884Li K, Tan K, Yacovelli A, Bi WG. Effect of botulinum toxin type A on muscular temporomandibular disorder: A systematic review and meta-analysis of randomized controlled trials. J Oral Rehabil. 2024 May;51(5):886-897. doi: 10.1111/joor.13648. Epub 2023 Dec 27.
- Results publication: PubMed 35448891Yoshida K. Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System. Toxins (Basel). 2022 Apr 14;14(4):282. doi: 10.3390/toxins14040282.
- Individual participant dataSharing planned: Undecided
Related trials for Masticatory Myofascial Pain Syndrome
Not yet recruitingPhase 2
MRI Study of OnabotulinumtoxinA (OnabotA) Effect on Jaw Muscle Pain
Masticatory Myofascial Pain Syndrome
RecruitingObservational study
Diffusion MRI for Quantitative Assessment of Myofascial Pain
Masticatory Myofascial Pain Syndrome
RecruitingPhase 4
EMG-Based Evaluation of Occlusal Splint and Masseter Botox Effects on Head and Neck Muscles
Myofascial Pain Syndrome (MPS), Masticatory Muscle Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Islam Kassem, PhD contact
Alshaimaa Mohamed principal investigator
Fayoum University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing conventional BoNT-A treatment and conventional treatment plus medial pterygoid injection in people with Masticatory Myofascial Pain Syndrome, run by Fayoum University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alshaimaa Mohamed, PhD (00201006047940, aas16@fayoum.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
pain intensity (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07774884, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.